Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Avax enters research agreement with University of Tokyo for breast cancer vaccine

May 21, 1999

AltaRex grants Purdue Pharma an option to license two AIT products

May 18, 1999

Onyvax licenses anticancer vaccine from CRCT

May 17, 1999

Ligand confirms that ECOG has initiated multicenter phase II study of Ontak for NHL

May 13, 1999

Promising phase I/II results for Leuvectin in prostate cancer presented at AUA meeting

May 5, 1999

Cantab in-licenses Novasomes adjuvant for use in TA-CIN vaccine; clinical testing in sight

April 26, 1999

Promising results reported at AACR meeting from M-Vax trial in advanced melanoma

April 21, 1999

Recombinant immunotoxin for hematological malignancies from NCI evaluated in phase I

April 20, 1999

Immunological response to GMK melanoma vaccine examined as part of phase III trial

April 19, 1999

NIH investigates next-generation cancer immunotherapeutic

April 14, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...